Kidney research and clinical practice · 2026
Prevalence of polypharmacy and its association with clinical outcomes in kidney transplant recipients : results from the KNOW-KT study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koo Tai Yeon, Choi Young Eun, Jang Yookyung, Oh Se Won, Yang Jaeseok, Huh Kyu Ha, Lee Kyo Won, Jung Hee-Yeon, Kang Kyung Pyo, Han Seungyeup, Ryu Jung-Hwa, Jo Sang-Kyung, Kim Myung-Gyu
Аннотация
BACKGROUND: Polypharmacy (PP) is common among kidney transplant recipients (KTRs) due to lifelong immunosuppressive therapy and comorbidity management. However, PP's impact on clinical outcomes remains unclear. In this study, we examine the association between PP and adverse outcomes in KTRs.
METHODS: We analyzed data of 972 KTRs from the Korean Cohort Study for Outcomes in Patients with Kidney Transplantation (KNOW-KT). Excessive PP (ePP) was defined as ≥10 medications at 1-year posttransplantation. Outcomes included all-cause mortality, graft failure, and cardiovascular events. Inverse probability of treatment weighting (IPTW) was used to balance the baseline characteristics.
RESULTS: ePP was present in 49% of the KTRs, averaging 9.8 medications. After IPTW, ePP was not significantly associated with allcause mortality or graft failure. However, ePP was significantly associated with an increased risk of cardiovascular events (hazard ratio [HR], 1.80; 95% confidence interval [CI], 1.07-2.96; p = 0.03). This association remained significant after accounting for death as a competing risk (HR, 3.23; 95% CI, 1.40-7.47; p = 0.006). Subgroup analysis showed that the association between ePP and cardiovascular events was more pronounced in male patients and those receiving lipid-lowering agents. Use of immunosuppressive agents was broadly comparable between groups.
CONCLUSION: ePP is highly prevalent among KTRs and is independently associated with an increased risk of cardiovascular events. This association appears to be primarily attributable to the overall PP burden. These findings highlight the importance of regular medication review and individualized pharmacologic strategies to optimize cardiovascular risk management in this population.
METHODS: We analyzed data of 972 KTRs from the Korean Cohort Study for Outcomes in Patients with Kidney Transplantation (KNOW-KT). Excessive PP (ePP) was defined as ≥10 medications at 1-year posttransplantation. Outcomes included all-cause mortality, graft failure, and cardiovascular events. Inverse probability of treatment weighting (IPTW) was used to balance the baseline characteristics.
RESULTS: ePP was present in 49% of the KTRs, averaging 9.8 medications. After IPTW, ePP was not significantly associated with allcause mortality or graft failure. However, ePP was significantly associated with an increased risk of cardiovascular events (hazard ratio [HR], 1.80; 95% confidence interval [CI], 1.07-2.96; p = 0.03). This association remained significant after accounting for death as a competing risk (HR, 3.23; 95% CI, 1.40-7.47; p = 0.006). Subgroup analysis showed that the association between ePP and cardiovascular events was more pronounced in male patients and those receiving lipid-lowering agents. Use of immunosuppressive agents was broadly comparable between groups.
CONCLUSION: ePP is highly prevalent among KTRs and is independently associated with an increased risk of cardiovascular events. This association appears to be primarily attributable to the overall PP burden. These findings highlight the importance of regular medication review and individualized pharmacologic strategies to optimize cardiovascular risk management in this population.